Chemotherapeutic targeting of myeloid-derived suppressor cells

Darya Alizadeh, Emmanuel Katsanis, Nicolas Larmonier

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.

Original languageEnglish (US)
Article numbere27338
Issue number1
StatePublished - 2014


  • Cancer
  • Chemoimmunomodulation
  • Doxorubicin
  • Helper T lymphocytes
  • Myeloid-derived suppressor cells
  • ROS

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Chemotherapeutic targeting of myeloid-derived suppressor cells'. Together they form a unique fingerprint.

Cite this